Skip to main content

Branded

  • Migraine pain — it’s big, it’s real and it’s underappreciated
    Nearly all respondents diagnosed with migraine (91%) agreed those who do not suffer from migraine do not understand the severity of the disease.

  • Teva launches Qvar RediHaler
    The product, which Teva said eliminates the need for hand-breath coordination, is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients ages four years and older.

  • Boehringer Ingelheim names new U.S. head
    Wolfgang Baiker will succeed the retiring Paul Fonteyne as Boehringer Ingelheim’s U.S. president and CEO, effective March 1.

  • Sanofi to acquire Bioverativ for $11.6B
    The acquisition will see Sanofi adding the Waltham, Mass.-based biopharmaceutical company's hemophilia treatments Eloctate and Alprolix to its specialty and rare disease portfolio.

  • FDA approves Avion Pharmaceuticals’ Balcoltra

  • ANI buys 4 products from AstraZeneca

    ANI Pharmaceuticals has acquired four potential new drugs from AstraZeneca, the Baudette., Minn.-based company announced recently. The company acquired the new drug applications and U.S. marketing rights to Atacand, Atacand HCT, Arimidex and Casodex for $46.5 million in cash, royalties and sales-based milestones.

  • Dr. Reddy’s launches Alkeran generic

    Dr. Reddy’s has announced the launch of melphalan hydrochloride for injection, which has been approved by the Food and Drug Administration. This latest product is a therapeutic equivalent generic version of Alkeran.

    The company’s Melphalan Hydrochloride for injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.

  • Teva restructures, shuffles executive team

    On the heels of its appointing a new CEO, Teva is restructuring itself and naming new executives in an effort it said would create strategic alignment across its portfolio, regions and functions and drive profits as it continues to face headwinds.

X
This ad will auto-close in 10 seconds